Answers are grounded in this paper and cite their sources.
There is a need for biosensing systems that can be operated at the point‐of‐care (POC) for disease screening and diagnostics and health monitoring. In spite of this, simple to operate systems with the required analytical sensitivity and specificity in clinical samples, using a sample‐in‐answer‐out approach, remain elusive. Reported here is an electrochemical bio‐barcode assay (e‐biobarcode assay) that integrates biorecognition with signal transduction using molecular (DNA/protein) machines and signal readout using nanostructured electrodes. The e‐biobarcode assay eliminates multistep processing and uses a single step for analysis following sample collection into the reagent tube. A clinically relevant performance for the analysis of prostate specific antigen (PSA) in undiluted and unprocessed human plasma: a log‐linear range of 1 ng mL −1 –200 ng mL −1 and a LOD of 0.4 ng mL −1 , was achieved. The e‐biobarcode assay offers a realistic solution for biomarker analysis at the POC.
No takes yet. Share an insight, caveat, or question.
Traynor et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: